New drug cocktail targets Hard-to-Treat HER2 cancers
NCT ID NCT06328738
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new drug called ELVN-002 in combination with trastuzumab and chemotherapy for people with advanced HER2-positive solid tumors, including breast, gastric, and colorectal cancers. The main goal is to find a safe dose and understand side effects. About 275 participants will be enrolled across multiple cancer types.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ELVN-002 (a targeted drug) combined with trastuzumab and chemotherapy drugs
- What this could lead to
- If successful, this could point toward a new treatment option for people with advanced HER2-positive cancers that have stopped responding to standard therapies.
- What could go wrong
- This is a very early (Phase 1) trial focused on safety and dosing, not yet on effectiveness. It is small and may not lead to a proven treatment. Side effects from the drug combinations are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
-
Azienda Ospedaliero Universitaria Pisana
Pisa, Italy
-
Azienda Ospedaliero-Universitaria Renato Dulbecco
Catanzaro, Italy
-
Azienda USL IRCCS di Reggio Emilia
Reggio Emilia, Italy
-
BRCR Medical Center Inc.
Plantation, Florida, 33322, United States
-
CHA Bundang Medical Center
Seongnam-si, 13496, South Korea
-
CHU de Liège
Liège, Belgium
-
CHU de Poitiers
Poitiers, 8600, France
-
Clinica univeritaria Navarra - Pamplonas
Pamplona, Spain
-
Clinica universitaria Navarra - Madrid
Madrid, 28027, Spain
-
Cliniques Universitaires Saint-Luc
Brussels, Belgium
-
Fondazione IRCCS San Gerardo dei Tintori
Monza, Italy
-
Fondazione Policlinico A. Gemelli IRCCS
Rome, 00168, Italy
-
Fundacion Instituto Valenciano de Oncologia
Valencia, Spain
-
GZA Ziekenhuizen - Campus Sint-Augustinus
Wilrijk, Belgium
-
Hospital Beata Maria Ana
Madrid, 28007, Spain
-
Hospital Universitari Dexeus - Grupo Quironsalud
Barcelona, Spain
-
Institut de Cancérologie Strasbourg Europe
Strasbourg, 67033, France
-
Institut de Cancérologie de l'Ouest
Saint-Herblain, France
-
Institut du Cancer de Montpellier - Val D'Aurelle
Montpellier, 34090, France
-
Instituto de Investigacion Oncologica Vall d'Hebron (VHIO) - EPON
Barcelona, Spain
-
Istituto Europeo di Oncologia
Milan, Italy
-
NEXT Oncology-Hospital Quironsalud Barcelona
Barcelona, 08023, Spain
-
NEXT Virginia
Fairfax, Virginia, 22031, United States
-
Radboud UMC
Nijmegen, Netherlands
-
START Barcelona_HM Nou Delfos
Barcelona, 08023, Spain
-
START Madrid - Hospital Universitario Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
Seoul National University Hospital
Soeul, South Korea
-
Severance Hospital, Yonsei University Health System
Seoul, 03722, South Korea
-
The Catholic University of Korea, St. Vincent's Hospital
Suwon, 16247, South Korea
-
Washington University
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who will survive a bowel surgery leak?
- Can a new drug outsmart resistant breast cancer?
- Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?
- Can a new targeted drug outperform the current standard for HER2-Positive breast cancer?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- A mobile app aims to turn health awareness into action — a trial puts it to the test